论文部分内容阅读
缺血性卒中是一个高发病率、高病死率、高致残率和高复发率的“四高”疾患,只有rt-PA超早期溶栓治疗有效。缺血性卒中患者发病4.5h之内静脉应用重组组织型纤溶酶原激活剂是非常有效的治疗办法,这一治疗方法的临床益处需要存在可挽救的半暗带。但由于时间窗的限制,能得到r-TPA溶栓治疗的患者很少。探讨在快速MRI指导下扩大时间窗静脉溶栓治疗急性脑梗死的可行性,评价其疗效及出血的不良反应。
Ischemic stroke is a “high” disease with high morbidity, high mortality, high morbidity and high relapse rate, and only rt-PA is effective in early thrombolytic therapy. Intravenous administration of recombinant tissue-type plasminogen activator within 4.5 hours of onset of ischemic stroke is a very effective treatment and the clinical benefits of this approach require the presence of salvageable penumbra. However, due to the limitation of time window, few patients can get r-TPA thrombolysis. To explore the feasibility of expanding the time window of intravenous thrombolysis in acute cerebral infarction under the guidance of rapid MRI to evaluate the curative effect and adverse reactions of bleeding.